Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 15, Issue 6, 2008, Pages 634-639

  Seo, Satoru ^a   Doi, Ryuichiro ^a   Machimoto, Takafumi ^a   Kami, Kazuhiro ^a   Masui, Toshihiko ^a   Hatano, Etsuro ^a   Ogawa, Kohei ^a   Higashi, Tatsuya ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

18 F Fluorodeoxyglucose; Diagnostic imaging; Invasive ductal carcinoma of the pancreas; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG UPTAKE; EARLY DIAGNOSIS; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; TUMOR DIFFERENTIATION; TUMOR VOLUME; CARCINOMA; CHI SQUARE DISTRIBUTION; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PANCREAS TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHI-SQUARE DISTRIBUTION; EARLY DIAGNOSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 56249112975     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-007-1339-x     Document Type: Article

References (44)

1. Fung MC, Sakata T. What's new in pancreatic cancer treatment? J Hepatobiliary Pancreat Surg 2002;9:61-75.
2. Matsuno S, Egawa S, Arai K. Trends in treatment for pancreatic cancer. J Hepatobiliary Pancreat Surg 2001;8:544-548.
3. Yamamoto M, Ohashi O, Saitoh Y. Japan Pancreatic Cancer Registry: current status. Pancreas 1998;16:238-242.
4. Edge SB, Schmieg RE Jr, Rosenlof LK, Wilhelm MC. Pancreas cancer resection outcome in American University centers in 1989-1990. Cancer 1993;71:3502-3508.
5. Kawarada Y, Das BC, Naganuma T, Isaji S. Surgical treatment of pancreatic cancer. Does extended lymphadenectomy provide a better outcome? J Hepatobiliary Pancreat Surg 2001;8:224-229.
6. Imaizumi T, Hanyu F, Harada N, Hatori T, Fukuda A. Extended radical Whipple resection for cancer of the pancreatic head: Operative procedure and results. Dig Surg 1998;15:299-307.
7. Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kayahara M, Ohta T, et al. Results of extensive surgery for pancreatic carcinoma. Cancer 1996;77:640-645.
8. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671-1677.
9. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59-66.
10. Livingston EH, Welton ML, Reber HA. Surgical treatment of pancreatic cancer. The United States experience. Int J Pancreatol 1991;9:153-157.
11. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. One hundred and eighteen consecutive resections without an operative mortality. Ann Surg 1990;211:447-458.
12. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993;217:430-435; discussion 5-8.
13. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control 2006;17:403-409.
14. Japan Pancreas Society. Classification of pancreatic carcinoma. 2nd English ed. Tokyo: Kanehara; 2003.
15. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13:427-433.
16. Murguia E, Quiroga D, Canteros G, Sanmartino C, Barreiro M, Herrera J. Gallbladder metastases from ductal papillary carcinoma of the breast. J Hepatobiliary Pancreat Surg 2006;13:591-593.
17. Chikamoto A, Tsuji T, Takamori H, Kanemitsu K, Uozumi H, Yamashita Y, et al. The diagnostic efficacy of FDG-PET in the local recurrence of hilar bile duct cancer. J Hepatobiliary Pancreat Surg 2006;13:403-408.
18. Maemura K, Takao S, Shinchi H, Noma H, Mataki Y, Kurahara H, et al. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 2006;13:435-441.
19. Delbeke D, Pinson CW. Pancreatic tumors: Role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004;11:4-10.
20. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US. Radiology 1995;195:345-352.
21. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18) F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-2554.
22. Yoshioka M, Sato T, Furuya T, Shibata S, Andoh H, Asanuma Y, et al. Role of positron emission tomography with 2-deoxy-2-[18F] fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J Gastroenterol 2004;39:50-55.
23. Lyshchik A, Higashi T, Hara T, Nakamoto Y, Fujimoto K, Doi R, et al. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest 2007;25:154-162.
24. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004;28:219-230.
25. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: A report of treatment and survival trends for 100 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
26. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
27. Sheridan MB, Ward J, Guthrie JA, Spencer JA, Craven CM, Wilson D, et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: A comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol 1999;173:583-590.
28. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Ohtomo K, Kinoshita T, et al. Pancreatic ductal adenocarcinoma: Preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997;202:655-662.
29. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, et al. Pancreatic tumors: Comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998;170:1315-1322.
30. Tabuchi T, Itoh K, Ohshio G, Kojima N, Maetani Y, Shibata T, et al. Tumor staging of pancreatic adenocarcinoma using early-and late-phase helical CT. AJR Am J Roentgenol 1999;173:375-380.
31. Irie H, Honda H, Kaneko K, Kuroiwa T, Yoshimitsu K, Masuda K. Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma. Abdom Imaging 1997;22:429-433.
32. DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004;141:753-763.
33. Bronstein YL, Loyer EM, Kaur H, Choi H, David C, DuBrow RA, et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol 2004;182:619-623.
34. Mehmet Erturk S, Ichikawa T, Sou H, Saitou R, Tsukamoto T, Motosugi U, et al. Pancreatic adenocarcinoma: MDCT versus MRI in the detection and assessment of locoregional extension. J Comput Assist Tomogr 2006;30:583-590.
35. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-1674.
36. Eary JF, Conrad EU. Positron emission tomography in grading soft tissue sarcomas. Semin Musculoskelet Radiol 1999;3:135-138.
37. Stokkel MP, ten Broek FW, van Rijk PP. The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol 1998;34:466-471.
38. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, et al. 18 Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729-737; discussion 37-38.
39. Berberat P, Friess H, Kashiwagi M, Beger HG, Buchler MW. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999;23:882-887.
40. Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 2001;234:675-680.
41. Imdahl A, Nitzsche E, Krautmann F, Hogerle S, Boos S, Einert A, et al. Evaluation of positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194-199.
42. Clark L, Perez-Tamayo RA, Hurwitz H, Branch S, Baillie J, Jowell P, et al. The role of positron emission tomography in the diagnosis and staging of pancreatic cancer (abstract). Gastroenterology 1998;114:S0044.
43. Yonekura Y, Benua RS, Brill AB, Som P, Yeh SD, Kemeny NE, et al. Increased accumulation of 2-deoxy-2-[18F] fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982;23:1133-1137.
44. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998;39:1727-1735.